About one in eight adults have taken a drug belonging to the GLP-1 class of medications for weight loss and related ...
A poll from the health policy nonprofit KFF found that 1 in 8 adults say they’ve taken a GLP-1 agonist, the obesity and ...
I’M MINDY BASARA IN TODAY’S MEDICAL ALERT, WEIGHT LOSS AND DIABETES DRUGS LIKE OZEMPIC WEGOVY AND ZYBAN ARE ALL THE RAGE ...
A KFF poll also suggests half of the respondents who had tried these weight loss meds no longer took them, with many ...
A wide swath of Americans are using GLP-1s despite shortages, a survey says. Meanwhile, Google DeepMind’s new AI model can ...
One in eight adults (12 percent) say they have ever taken a glucagon-like peptide-1 receptor agonist (GLP-1 RA) and 6 percent ...
Other findings from the latest Kaiser Family Foundation Health Tracking Poll shed light on public awareness, use, and ...
The benefit-harm balance of initiating Glucagon-like Peptide-1 (GLP-1) receptor agonists (RAs) versus a placebo intervention.
The number of American teens and young adults who've been prescribed one of the new GLP-1 weight-loss drugs soared nearly ...
Injected medications that treat diabetes and obesity increase the risk of a rare but serious side effect: stomach paralysis, ...
Agents in development would preserve lean body mass and further promote fat loss in people taking new antiobesity medications ...
Most users say they took the drug to treat a chronic condition, including diabetes or heart disease. HealthDay News — One in 8 adults (12%) say they have ever taken a glucagon-like peptide-1 receptor ...